FDA Warns Siemens On Marketing Claims For Syngo Arterial Health Package
This article was originally published in The Gray Sheet
Executive Summary
FDA's recent warning letter to Siemens Medical is an example of the agency's recent crackdown on unapproved marketing and promotional claims by device manufacturers
You may also be interested in...
FDA Surveillance Of Ads, Promotional Materials To Increase
FDA says it is stepping up surveillance of advertising and promotional materials for medical devices
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.